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KEY POINTS
 The CD301 cutaneous lymphoproliferative disorders can look similar both clinically and histologi-
cally. Evaluation by a clinician and dermatopathologist with expertise in cutaneous lymphomas is
invaluable in the correct classification of these disorders.
 Correct classification sets the stage for choosing an appropriate treatment regimen for each of
these disorders. Lymphomatoid papulosis (LyP) rarely requires systemic therapy, whereas refrac-
tory or multifocal cutaneous anaplastic large cell lymphoma (cALCL) and mycosis fungoides (MF)
with large cell transformation (LCT) may require systemic therapy in combination with skin-
directed therapy.
 Given the chronic nature and typical good prognosis of most CD301 lymphoproliferative disorders
(LPDs), the clinician should take into account possible deleterious long-term side effects of treat-
ment options.INTRODUCTION
Primary cutaneous CD301 LPDs account for
approximately 25% of cutaneous lymphomas.1
The peak incidence is in the fifth and sixth de-
cades. Although these CD301 LPDs are clinically
heterogeneous, they can be indistinguishable his-
tologically. The 2 CD301 primary cutaneous LPDs
listed in the World Health Organization European
Organization for Research and Treatment of Can-
cer (EORTC) classification scheme are LyP and
primary cALCL2; however, it is important to include
LCT of MF in this discussion as these 3 CD301
LPDs can mimic, be mistaken for, and occur
concomitantly with each other. Recognizing and
differentiating these CD301 entities can be chal-
lenging, but correct classification is imperative
for developing an effective treatment protocol.
There is no definitive test to differentiate these 3Author disclosures: Investigator for Kyowa and Eisai.
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pathologic data remains the best method to
date. By observing the primary lesion morphology,
distribution on the body, the natural course of the
lesions, the histology, and the immunohistochem-
ical data, more often than not, one can correctly
categorize the disorder.
Many different treatment strategies have been
used for the CD301 LPDs; however, given the rar-
ity of these diseases, there are little accumulated
data for evidence-based guidelines. Most studies
are case reports, small series, or retrospective re-
views. There are very few prospective studies.
However, the EORTC, International Society for
Cutaneous Lymphomas (ISCL), and the US Cuta-
neous Lymphoma Consortium (USCLC) recently
convened an expert multidisciplinary panel and
offered recommendations for treatment of LyP
and cALCL based on literature analysis andSouth, EFH 414, Birmingham, AL 35294, USA
blished by Elsevier Inc. This is an open access article
org/licenses/by-nc-nd/4.0/).
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Hughey820discussion by clinicians.3 The National Compre-
hensive Cancer Network (NCCN) guidelines are
also a great Web-based reference to aid in the
workup and treatment of CD301 LPDs (www.
nccn.org).
The following discussion offers practical pearls
to differentiate entities, addresses most of the
treatment options, and addresses the treatment
of MF with LCT, which was not discussed in the
prior review.LYMPHOMATOID PAPULOSIS
Whether to classify LyP as benign or malignant re-
mains a controversy. However, most experts in the
field think of LyP as an indolent cutaneous lym-
phoma on the same spectrum as cALCL. LyP inci-
dence peaks in the fifth decade and has an
excellent prognosis with a 10-year survival ap-
proaching 100% (LyP).1 Up to70% of LyP cases
are associated with 1TCR gene rearrangements.4
The classic clinical description of LyP is crops of
erythematous papules (often at different stages of
development) most often on the trunk or proximal
extremities that progress to central necrosis and
heal spontaneously over weeks to possiblymonths
(Fig. 1). The histology can be variable with predom-
inant CD41 or CD81 T cells and is categorized into
5 different subtypes (A–E) (Table 1), although a sin-
gle patient may exhibit several of these histologic
patterns. These subtypes are not predictive of clin-
ical course or of severity of disease. However, it is
important to be knowledgeable about these histo-
logic subtypes as they mimic the histology of other
more concerning LPDs and may lead to misdiag-
nosis and possibly more aggressive treatment
than is needed.
The most common type A LyP histology resem-
bles wedge-shaped clusters of CD301 large atyp-
ical lymphocytes interspersed between a mixedFig. 1. Lymphomatoid papulosis: crops of clustered
papules often with central eschar.inflammatory infiltrate of neutrophils, histiocytes,
eosinophils, and smaller lymphoctyes, and epider-
motropism is typically absent. The rarer type B LyP
exhibits histologic features reminiscent of MF, with
a bandlike infiltrate and epidermotropism of small
to medium atypical lymphocytes that may be
CD30. Type C LyP is described as cALCL-like
with larger clusters or sheets of large anaplastic
CD301 atypical lymphocytes without the mixed in-
flammatory infiltrate seen in type A. Type D LyP
has a more worrisome histologic appearance and
can mimic CD81 aggressive epidermotropic cuta-
neous T-cell lymphoma (CTCL) with large CD81,
CD301 lymphocytes that stain for cytotoxic
markers, including T-cell intracellular antigen-1
(TIA-1), granzyme, and perforin.5 These cases do
not usually have necrosis and ulceration but may
lose expression of T-cell antigens including CD2,
CD3, CD5, and CD7. Recently reported type E
LyP is described as angioinvasive with small, me-
dium, and large angiocentric CD301 atypical lym-
phocytes that invade the walls of small to medium
vessels in the dermis and less so in the subcutis,
often with associated necrosis.6 Clinically, the
initial papules in type E LyP quickly progress to
larger hemorrhagic and necrotic ulcers, but even
these cases follow the typical course of LyP and
spontaneously resolve.7,8 In addition, one case se-
ries describes LyP type F, which exhibits perifollic-
ular infiltrates of CD301 atypical cells with
folliculotrophism with or without follicular
mucinosis.9
LyP may occur in conjunction with other lym-
phomas in about 20% of cases.10 There have
been reported cases of LyP in association with
cALCL, MF, Hodgkin disease, systemic ALCL,
and other systemic lymphomas. In some of these
cases, the same clone is responsible for both dis-
eases, suggesting a possible common origin in
the precursor lymphoid stem cell.11–13 The coexis-
tence of these disorders can lead to confusing clin-
ical presentations making accurate diagnosis
challenging. In these situations, it is important to
remember that performing multiple biopsies of
each different primary lesion morphology and
observing the course of individual lesions can be
helpful in deciphering these cases. In addition, if
LyP nodules begin to exceed 1 cm, one should be
suspicious for progression to another subtype of
cutaneous lymphoma.13Treatment of Lymphomatoid Papulosis
Despite the excellent prognosis of LyP, the recur-
rent nature of the lesions is typically bothersome
for patients, and most desire treatment (Box 1).
Although topical corticosteroid therapy does not
Table 1
Lymphomatoid papulosis subtypes
LyP Subtypes Histologic Description
Type A Wedge-shaped clusters CD301 large atypical lymphocytes interspersed with a mixed
inflammatory infiltrate of neutrophils, histiocytes, and eosinophils
Type B MF-like with bandlike infiltrate and epidermotropism of smaller atypical lymphocytes
that may be CD30
Type C cALCL-like with larger clusters or sheets of large anaplastic CD301 cells without the
interspersed mixed infiltrate of Type A
Type D CD81 epidermotropic CTCL-like with large CD81, CD301 lymphocytes that often stain
with cytotoxic markers (TIA-1, granzyme, perforin)
Type E Angioinvasive with small to large angiocentric CD301 atypical lymphocytes that
invade walls of small to medium vessels in dermis or SQ
Type F Perifollicular infiltrates of CD301 atypical cells with folliculotrophism with or without
follicular mucinosis
Abbreviations: CTCL, cutaneous T-cell lymphoma; SQ, subcutaneous; TIA-1, T-cell intracellular antigen-1.
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disease, spot treatment with a high-potency
topical steroid can be helpful to reduce the size
and to hasten involution of papules. For those pa-
tients with frequent outbreaks of many LyP lesions,
treatment options that may prevent occurrence of
new lesions are often desirable and may include
single-agent systemic immunomodulators, che-
motherapy, and/or phototherapy. However, given
the excellent prognosis of LyP, the long-term
sequela of these therapies should be considered.
There is no role for multiagent chemotherapy for
LyP, as the risks likely outweigh the benefits.
According to the EORTC, ISCL, and USCLC
recent review,3 topical corticosteroids, metho-
trexate (MTX), and psoralen 1 ultraviolet A (PUVA)
are all first-line therapies successful at obtaining a
partial response (PR) or complete response (CR)Box 1
Lymphomatoid papulosis treatment options
Skin-directed treatment options
 Observation
 Topical corticosteroids
 Phototherapy
 Topical imiquimod
 Topical nitrogen mustard
 Interferon intralesional (IL)
Systemic treatment options
 Methotrexate
 Oral retinoids
 Interferonin LyP. Thus, the decision on which of these treat-
ments to choose depends on the extent of the pa-
tient’s disease (Is it too widespread for topical
treatment?), where the patient lives (Are they within
driving distance of a phototherapy unit?), their in-
surance situation (Are they insured and does their
insurance cover the pharmacy cost of psoralen?),
and their comorbidities (Is any preexisting liver dis-
ease or poor kidney function making them a poor
candidate for MTX?). Other second- and third-line
treatment options are also discussed.
Topical corticosteroids
Althoughmonotherapy with topical corticosteroids
does not prevent new lesions, they do typically
help the lesions remain smaller and resolve faster
and therefore are a good option for patients with
limited and infrequent disease outbreaks. Topical
corticosteroids are also used often as adjunctive
treatment along with MTX or PUVA. Of the 25 pa-
tients with LyP reviewed by Kempf and
colleagues,3 only 3 had a CR with topical cortico-
steroids reflecting that, although helpful, mono-
therapy with topical corticosteroids rarely
achieve CRs in LyP. Given the chronic nature of
LyP, the risks outweigh the benefits for oral sys-
temic corticosteroids, and they have not been
shown to be effective in LyP.14
Phototherapy
There is a lack of published data on the use of pho-
totherapy (PUVA) for LyP, but there is ample anec-
dotal evidence and small case series to strongly
support its use as a first-line treatment modality
for LyP.15 Kempf and colleagues3 reported in their
review of 19 patients with LyP published in the
literature that 68% had a PR and 27% had a CR
Hughey822with PUVA therapy. Relapses occurred in all pa-
tients shortly after discontinuing light therapy. An
example of a typical PUVA regimen for patients
with LyP or MF begins with treatments 3 times
weekly according to institution protocols and
skin type of the patient. Once the patient has sub-
stantial improvement, PUVA frequency can be
decreased to twice per week, then to once per
week, then to once every other week, then once
every third week, and so on until reaching the min-
imum maintenance dose appropriate to keep that
patient’s disease not 100% clear but rather well
controlled. Discussing realistic expectations with
patients is important. It may take a year or more
to reach the desired maintenance frequency with
PUVA. The minimum frequency of PUVA mainte-
nance therapy is typically once every 8 weeks.
There are also reports of effectiveness with ultra-
violet B (UVB) phototherapy in 6 of 7 children with
LyP.16 Although UVB therapy does not penetrate
to the depth that PUVA reaches to treat thicker le-
sions, it still may be effective for thinner LyP le-
sions. Broadband UVB (BBUVB) and narrowband
UVB (NBUVB) also typically start with a 3-times-
per-week treatment regimen until the patient sub-
stantially improves. Then one can further decrease
the frequency to twice per week, then to once per
week, and then every other week. Further de-
creases in BBUVB and NBUVB may lead to loss
of efficacy and increased potential for phototox-
icity. This every-other-week maintenance UVB
regimen may be safely continued for extended pe-
riods in an effort to control disease. Although PUVA
is associatedwith increased risk of bothmelanoma
and nonmelanoma skin cancers, NBUVB does not
have this same association.17–19
One case report heralded the success in treating
refractory LyP lesions with methyl aminolevulinate
photodynamic therapy (MAL PDT) with a 630-nm
light source after 3 hours of incubation under oc-
clusion. MAL PDT was repeated 1 week later,
and refractory lesions resolved 7 days after the
second treatment without recurrence of lesions
in the treated area during an 11-month follow-up
period.20 PDT treatment may prove useful as field
treatment in patients with recurrent or refractory
lesions of LyP within a localized area.
The 308-nm excimer laser has been used for the
treatment of localized LyP lesions. A total of 13
treatments given 3 times weekly with a maximum
fluence of 500 mJ/cm2 induced clearance in 75%
of treated lesions in one report; however, duration
of response was not addressed.21
In one LyP case, extracorporeal photopheresis
with 8-methoxypsoralen was used on 2 consecu-
tive days once monthly to achieve a PR, albeit
temporary, in this refractory case of diffuse LyP.22Methotrexate
MTX is a folate antagonist that inhibits purine and
pyrimidine synthesis. Despite few published re-
ports,23–26 MTX is an accepted first-line treatment
of CD301 LPDs, and there are ample anecdotal
successes in controlling CD301 LPDs with low-
dose MTX. Effective doses range from 10 to
25 mg oral once weekly typically with concomitant
folic acid, 1 mg, each day. The largest study using
MTX included cALCL as well as LyP. Of 45 pa-
tients, 39 (87%) had satisfactory long-term control
of their disease.27 Doses in some patients reached
60 mg per week; however, the investigators found
that patients responded equally well with lower
doses in the range of 15 to 20 mg per week. The
patients typically responded within 4 weeks of
beginning therapy. Once improvement was seen,
MTX frequency was reduced in an effort to retain
control of disease while reducing risk of drug
toxicity. In some patients MTX could be reduced
to once every 10 to 28 days with good control of
CD301 lesions but with less control of the MF
patches (in the patients with coexisting MF). Me-
dian total duration of MTX therapy exceeded
39 months (range, 2–205 months). After MTX was
discontinued, 10 patients remained free of disease
from 24 to 227 months. The most common side ef-
fects reported were fatigue (47%), elevated liver
transaminase levels (27%), and nausea (22%). Of
10 patients treated withMTX for more than 3 years,
5 had evidence of hepatic fibrosis.27
Subcutaneous (SQ) administration of MTX can
be considered in patients not responding to oral
dosing.13 There is one report of topical MTX use
in a patient with LyP whomoistened his MTX tablet
with tap water and applied it to some of his LyP le-
sions. He essentially used his other LyP lesions as
a control and found that the lesions treated with
topical MTX resolved faster and stayed smaller
than the controls. MTX is known to have poor
percutaneous systemic absorption; therefore, the
effect of the MTX is thought to be local in this
case.28 Given the issues with cutaneous absorp-
tion, no commercially available topical MTX exists,
making this treatment modality difficult to repli-
cate; however, a previous phase 1/2 trial of a
topical MTX-laurocapram topical hydrophilic gel
did show some efficacy in CTCL, and similar com-
pounds may hold promise for the future.29
Bexarotene
Bexarotene is an oral retinoid with a high affinity for
the retinoid X receptor (RXR). It was approved
by the US Food and Drug Administration (FDA)
for the treatment of CTCL in 1999. In a prospective
study of 10 patients with LyP treated with either
topical or oral bexarotene, 300 mg/m2/d, all
Management of CD30+ Lymphoproliferative Disorders 823patients had a response in regards to decreased
number or duration of lesions, with an objective
response seen in 8 of 10 patients (1 CR in a patient
using oral bexarotene, with all lesions clearing and
no new lesions during continued therapy; 1 CR
and 5 PRs in treated lesions in patients using bex-
arotene gel; and 1 PR in a patient using both oral
and topical bexarotene).30 The use of bexarotene
gel was associated with more rapid disappear-
ance (average of 3 days to resolve compared
with 2–4 months for lesion resolution), less necro-
sis, and overall fewer lesions than before the pa-
tient started using bexarotene gel. One patient
with recurrent LyP lesions in a localized area expe-
rienced a reduction of new lesions after field treat-
ing the area with bexarotene gel, suggesting that
bexarotene gel may be useful in treating active le-
sions as well as preventing new lesions. Bexaro-
tene gel can cause an intense retinoid dermatitis
in some patients; therefore, counseling patients
on what to expect, allowing a reduction from the
recommended 4 times a day dosing for MF, and
prescribing a topical corticosteroid to calm reti-
noid dermatitis can encourage patient compliance
and continued therapy.30
A more extensive review of bexarotene is
offered by Dr. Huen AO; however, it is important
to mention here the central hypothyroidism and
hypertriglyceridemia seen with oral bexarotene.
Thyroid-stimulating hormone remains low
throughout oral bexarotene therapy because of
central hypothyroidism; therefore, it is the free T4
that must be followed to titrate the thyroid supple-
mentation dose. Communicating with the patient’s
primary doctor is of utmost importance in patients
administered oral bexarotene so that there is joint
understanding of the thyroid tests used to monitor
these patients. For lipid control, a fenofibrate or
statin should be administered at the same time
as oral bexarotene with subsequent monitoring
of the fasting lipid panel to adjust these medica-
tions as needed.
Interferon
There are little published data about the use of in-
terferons (IFNs) for CD301 LPDs.31 In an open trial
of patients with LyP, 5 patients were treated with
IFN-a SQ injection 3 times per week for 6 weeks
(1 with 15 million units (MU) 3 times per week, 4
with 3 MU 3 times per week). There were 4 CRs
and 1PR. The 2 of 5 patientswhohad recurrent dis-
ease shortly after IFN discontinuation were only
treated with 5 to 7 months of IFN suggesting that
it is difficult to alter the chronic recurring nature of
LyP with only short-term IFN use. One of these pa-
tients was then able to regain CR with subsequent
additional 17 months of IFN therapy and hasmaintained remission for 3 years. The other patient
with recurrent disease was treated with an addi-
tional 12 months of IFN and still has stable disease
31 years later. The other 3 patients were treated for
longer 12- to 13-month intervals with IFN and were
able to maintain their remission throughout the
follow-up period after drug discontinuation (from
1 to 11 years) and did not require any retreatment,
suggesting that treating with IFN for at least
1 year may yield better long-term results.32
Intralesional IFN has been used successfully for
larger, more refractory lesions. One report
described 1 MU intralesional injection of IFN-a2b
into 3 LyP lesions (3 MU total) 3 times weekly. Le-
sions smaller than 0.5 cm resolved after 3
injections. The larger lesions took up to 3 to 10 in-
tralesional injections. After resolution of lesions,
maintenance therapy was continued with 3 MU
SQ injection into the abdomen 3 times weekly.
The patient reported some skin recurrences; how-
ever, overall number and size of skin lesions were
reduced while on IFN therapy.33
Imiquimod
Imiquimod is a Toll-like receptor 7 and 8 agonist.
This topical immune response modifier enhances
the TH1 response leading to increased production
of IFN-a, interleukin 12, IFN-g, and other cytokines
thereby having an antitumor effect and balancing
the TH2 profile of CTCL.
34,35 One report of topical
imiquimod application 3 times a week in a patient
with LyP, who was already administered low-dose
MTX, noted a faster regression of lesions from his
typical 2 months down to 2 weeks.36 Imiquimod
seemed to have only a local effect as new lesions
appeared elsewhere in the patient, but this topical
immunomodulator provides a good option for
adjunctive treatment of refractory LyP lesions.
Topical nitrogen mustard
Despite a lack of published data, topical nitrogen
mustard is used often in clinical practice for refrac-
tory LyP lesions. A review of CD301 LPD treat-
ments found that only 1 of 17 patients with LyP
had a sustained response with topical nitrogen
mustard.3 However, sustained responses are often
not plausible in this chronic, relapsing, and remit-
ting disease, and nitrogen mustard should be
considered in the armamentarium of LyP treat-
ments. More studies need to be done to assess
whether its use leads to faster resolution of lesions.
PRIMARY CUTANEOUS ANAPLASTIC LARGE
CELL LYMPHOMA
Primary cALCL typically presents as a solitary or
few tumor nodules without evidence of extracuta-
neous disease at the time of diagnosis (Fig. 2).
Fig. 2. Primacy cutaneous anaplastic large cell lym-
phoma tumor.
Box 2
Primary cutaneous anaplastic large cell
lymphoma treatment options
Skin-directed treatment options
 Excision
 Radiation
 Topical imiquimod
 Phototherapy
 Interferon intralesional (IL)
Systemic treatment options
 Brentuximab vedotin
 Methotrexate
 Retinoids
 Interferon
 Gemcitabine
 Etoposide
Hughey824These nodules may progress to ulceration, and,
although up to 25% to 44% may show partial
regression over time, they less commonly
completely resolve on their own.1,10 Despite
various treatment strategies, up to 60% of patients
with cALCL have recurrences of skin nodules.3,37
Regional lymph node involvement may infre-
quently occur and is typically not associated with
a worse prognosis. Widespread systemic involve-
ment is rare,1 and when it occurs, the patient
would be considered to have systemic ALCL.
cALCL has an excellent prognosis of more than
90% 10-year survival; however, patients with
multifocal cALCL (lesions in more than 1 anatomic
area) are more at risk for extracutaneous spread.38
In addition, extensive extremity involvement can
prove refractory to therapy and may be associated
with a worse prognosis.39 Histologically, these tu-
mors comprise large sheets of anaplastic, pleo-
morphic, or immunoblastic T cells with irregularly
shaped nuclei and pale cytoplasm, which extend
into the deep dermis or SQ tissue and are
CD301 and anaplastic lymphoma kinase (ALK-1)
negative. Surrounding eosinophils and small reac-
tive lymphocytes may be seen at the periphery of
the infiltrate. By definition, CD30 is expressed by
greater than 75% of the large tumor cells.2Treatment of Cutaneous Anaplastic Large Cell
Lymphoma
Approximately one-fourth of cALCL lesions may
spontaneously improve or even resolve
(Box 2).1,13,40,41 Surgical excision and/or local radi-
ation therapy are reasonable options for the treat-
ment of solitary or localized cALCL. There is no
literature to suggest that radiation following exci-
sion has a better outcome than either treatment
modality alone. However, despite these 2 treat-
ment options, cALCL recurs in about 40% ofpatients either in the same or in a new location.
Multifocal lesions or frequent recurrences leading
to multiple surgical excisions and radiation
exposures become less appealing. In these situa-
tions, moving from a skin-directed to a systemic
single-agent immunomodulator or chemothera-
peutic treatment regimen offers a good alternative.
Low-dose MTX, oral retinoids (isotretinoin, acitre-
tin, or bexarotene), brentuximab vedotin, gemcita-
bine, IFN, or etoposide have data to support their
efficacy in this condition and are discussed in
detail.
Multiagent chemotherapies do not offer better
long-term response rates nor do they offer fewer
relapses compared with excision and/or radio-
therapy. Weighing risks versus benefits of the
long-term sequela of aggressive multiagent
chemotherapy regimens in this disease with excel-
lent prognosis is important. In a review article sum-
marizing several studies, multiagent C: cytoxan
(cyclophosphamide), H: adriamycin (hydroxy
doxorubicin), O: vincristine (Oncovin), P: predni-
sone (CHOP) chemotherapy offered CRs in
approximately 85% of patients receiving that
therapy; however, relapse rates in the various re-
viewed studies approached 71%, and the median
duration of response for some of these patients
was as short as 6 weeks.1,3 Multiagent CHOP
chemotherapy has not been shown to be superior,
and in fact may lead to more frequent subsequent
relapses than other treatment regimens.1,38
Although its use is not addressed further in this
article, it may be used for the rare case of refrac-
tory or widespread extracutaneous disease.
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Surgical excision is a well-accepted and first-line
treatment strategy for solitary cALCL of reasonable
size.3,38 There is noconsensusonmargins for tumor
removal. Removal of clinically abnormal-appearing
skin with small margins are accepted; however,
Mohs surgery does not likely offer any benefit, as
it is difficult to decipher margin of tumor compared
with surrounding inflammatory lymphocytes on
frozen section, which may lead to larger-than-
necessary margins. Whether there is any signifi-
cance of leaving positive margins is not known.
Radiotherapy
Local radiation therapy is a first-line monotherapy
for single or few localized lesions of cALCL. A
recent review found that successful local electron
beam radiation doses typically ranged from 30 to
46 Gy. About 2- to 4-cm margins of uninvolved
skin were included in the radiation field. Radiation
dermatitis and other side effects such as skin atro-
phy, sweat gland dysfunction, alopecia, and
edema were mild and tolerable. Although 95% of
patients in the review had a CR, 41% recurred
within the follow-up period of 22 months. Of 11 pa-
tients treated with surgical excision followed by ra-
diation, 67% experienced a sustained CR, but
64% had recurrence within 54 months.42
Brentuximab vedotin
SGN-30, the monoclonal antibody without any
chemotherapy attachment, is no longer available;
therefore, this discussion concentrates on SGN-
35 (brentuximab vedotin [BV]). BV is a CD30
monoclonal antibody conjugated to the chemo-
therapy monomethyl auristatin E, which inhibits
microtubule polymerization, leading to cell death.
This antibody-drug conjugate has been successful
in treating CD301 LPDs. BV is only FDA-approved
drug for CD301 systemic ALCL and relapsed/re-
fractory Hodgkin lymphoma; however, data sup-
port its use in other CD301 LPDs.43–49 A phase 2
single-center trial of 56 patients with CD301
CTCL (MF with LCT, n 5 28; LyP, n 5 9; cALCL,
n 5 2; and patients with mixed lesions unable to
be classified clearly, n 5 9) treated with BV re-
vealed objective response rates (PR plus CR) of
73% across all disease types. Dosing in this phase
2 trial was 1.8 mg/kg intravenously (IV) over 30 mi-
nutes every 21 days with dose reduction to
1.2 mg/kg if needed for adverse effect manage-
ment. Of 56 patients, 12 (21%) required dose ad-
justments secondary to peripheral neuropathy (9
patients), liver dysfunction (2 patients), and arthral-
gias (2 patients). Both patients with cALCL had
CRs, and 5 of 9 (55%) patients with LyP had CR,
with the remaining having greater than 50%reduction in lesion count. Of 9 patients with mixed
lesions, 8 (88%) had CRs, and the remaining pa-
tient had a PR. Median time to response was
3 weeks (range, 3–9 weeks), and median duration
of response was 26 weeks (range, 6–44) for
cALCL, LyP, and mixed lesions. Disease recurred
in most cases when BV was discontinued. Nausea
and neutropenia were the only grade 3 adverse
events, but overall, most adverse events were
mild. Although 65% of patients experienced pe-
ripheral neuropathy, it resolved in 45% of patients
after a median of 41.5 weeks.50
These trial data have led to using BV in the clin-
ical setting. For cALCL, as long as the patient does
not have peripheral neuropathy or other adverse
effects, the 1.8-mg/kg dosing every 21 days can
be continued until lesions are clear and then fol-
lowed with 2 additional doses, after which a wait
and see approach is taken. If new lesions occur
or old lesions recur, 1 to 2 additional doses of BV
can be given. Using BV on an as-needed basis
can extend the use of this drug while reducing like-
lihood of side effects. This same plan can be used
with the lower 1.2-mg/kg dosing regimen if neu-
ropathies are an issue. Finding an end point for
BV in the treatment of LyP is more difficult given
the recurrent crops of lesions that tend to recur
once BV is discontinued. In addition, although
rare, there have been at least 8 reported cases of
progressive multifocal leukoencephalopathy asso-
ciated with BV (2 of whom had CTCL).51 Therefore,
BV may be best used to gain control over severe
LyP cases to bridge them to other maintenance
therapy, but its use in indolent low-level disease
is likely not warranted.
Methotrexate
Oral MTX experience with cALCL has already been
discussed earlier in the LyP section; however, to
summarize, doses of 15 to 20 mg once weekly is
typically effective for controlling cALCL. Dose fre-
quency may be decreased as disease responds.
Intralesional MTX has also been used with varying
dosing regimens.24 One report noted a CR to a
cALCL leg lesion with 12.5 mg MTX intralesional
injection followed by another 10-mg injection
1 week later. No recurrence of the tumor nodule
was noted in the 9-month follow-up period. Pain
at the injection site can be ameliorated with topical
or injected anesthetic agents before MTX injec-
tions.52 Low-dose MTX may also be used as main-
tenance therapy after excision or radiation of
cALCL lesions to prevent recurrence.27
Oral retinoids
There are only case reports or small series of reti-
noid use in cALCL, but anecdotally, they have
Hughey826been successful.53–56 Bexarotene doses are
typically low dose, ranging from 225 to
450 mg/d. Isotretinoin doses range from 0.5
to 1.0 mg/kg, and acitretin doses from 20 to
50 mg/d.38,56 The mechanism of action and phar-
macokinetics of retinoids are addressed else-
where in this issue.
Gemcitabine
Gemcitabine, a pyrimidine analogue that halts
DNA replication and leads to cell apoptosis, is suc-
cessfully used for the treatment of refractory or
advanced CTCLs.57 Typical gemcitabine dosing
for refractory CTCL is 1000 to 1200 mg/m2 IV
over 30 minutes on days 1, 8, and 15 of a 28-day
cycle.58 This dosing regimen is appropriate and
useful in CD301 LPDs; however, results can some-
times be achieved with lower-dose regimens
(750 mg/m2) or lower frequency of dosing (every
14–21 days). Gemcitabine is typically well toler-
ated in this patient population, but reported side
effects include hematologic, cardiac, hepatic,
and gastrointestinal effects.
Etoposide
Etoposide is a cytotoxic topoisomerase inhibitor
successfully used in refractory cALCL. In a recent
review, there were 3 PRs and 4 CRs in the 7 cALCL
cases treated with oral etoposide, 50 mg/d.59 Eto-
poside remains a well-tolerated therapeutic option
for refractory, multifocal cALCL.
Interferon
There is a paucity of literature,31,60,61 but some re-
ports do support the use of the immunomodulat-
ing agent IFN to promote return of TH1 cytokine
profile and improve skin lesions in CD301 LPDs
including cALCL.31,60 IFN may be used by intrale-
sional, SQ, or IV routes. Doses range from 9 to 18
MU each week given in divided doses. A common
regimen is 3 MU 3 times weekly intralesional in-
jection for refractory cALCL lesions, although
fewer units and less frequent dosing can also be
used.
Imiquimod
Success with the topical immunomodulator imi-
quimod has been reported in several cases of
cALCL.62 Two patients with solitary cALCL lesions
(10-mm nodule and 2  4-cm tumor), which had
been present for 6 and 10 months without resolu-
tion, were treated with topical imiquimod 5%
cream to the lesions 3 times weekly for 6 weeks.
Both patients had a CR, with no recurrence during
the 8-month follow-up.63 In another report, imiqui-
mod was used 3 times weekly on a patient with
cALCL, and CR was achieved.64Phototherapy
The 308-nm excimer UVB laser has been success-
fully used in the past for refractory patches or pla-
ques of MF, especially those that are in sanctuary
areas or those that have not responded to topical
medications. Similar scenarios could be consid-
ered for the use of excimer laser in localized or re-
fractory CD301 LPDs. One report described the
use of the excimer laser to treat a solitary CD301
LPD nodule (likely cALCL) twice weekly during 12
sessions starting at 150 mJ and increasing to
500 mJ by the end of the course. There was no
recurrence of the lesion in a 15-month follow-up
period.65
Background data suggest that the photosensi-
tizing agent used in photodynamic therapy is
preferentially absorbed by the activated T lympho-
cytes in cutaneous lymphomas and that PDT can
cause inhibition of and apoptosis in these T
cells.66–68 PDT is not widely used nor is there a
prescribed regimen for its use in CD301 LPDs;
however, this treatment modality may be an option
to consider for tumor debulking in patients with
cALCL. One report described a dramatic reduction
in size of a cALCL tumor. Histology showed
massive degeneration of lymphoma cells after
PDT treatments with 20% 5-aminolevulinic acid
occluded for 6 hours and then treated with visible
light in the spectrum of 630 to 700 nm for 20 mi-
nutes once daily on 9 consecutive days.69
Combination therapies
A combination of bexarotene and IFN-a has been
reported and is commonly used with success. In
one case report, low doses of each were used
(150 mg/d bexarotene and 3 MU SQ IFN-a 3 times
weekly) to achieve a rapid and complete remission
sustained during a 12-month follow-up period in a
patient with multifocal cALCL.60
Although there are reports of benefit of denileu-
kin diftitox for CD301 LPDs, the discussion of this
has been omitted from this article as this drug is
currently not available.MYCOSIS FUNGOIDES WITH LARGE CELL
TRANSFORMATION
The classic clinical presentation of LCT in MF oc-
curs as a new solitary pink to violaceous nodule
within a long-standing MF patch or plaque, abrupt
onset of multiple pink scattered nodules, or a new
or enlarging tumor nodule of MF (Fig. 3).70 How-
ever, LCT occurring in patches or plaques of MF
does not necessarily signify a change in disease
stage. LCT occurs in 8% to 55% of MF cases
and is more common in advanced disease. In
an article retrospectively studying long-term
Fig. 3. Large cell transformation of mycosis fungoides.
Box 3
Mycosis fungoides with large cell
transformation treatment options
Skin-directed treatment options (may be used
adjunctively with some systemic therapies)
 Topical nitrogen mustard
 Topical retinoids
 Phototherapy
Systemic treatment options
 Methotrexate
 Interferon
 Oral retinoids
 Pralatrexate
 Gemcitabine
 Pegylated liposomal doxorubicin
 Brentuximab vedotin
 Romidepsin
 Allogenic stem cell transplant
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found that 1.4% of stage I-IIA, 26% stage IIb,
2.8% stage III, 55% stage IVA, and 66% stage
IVB developed transformation.71 In addition to
advanced stage, histologic transformation within
the first 2 years of diagnosis also portends a worse
prognosis.72 Although the transformed clone often
matches the original MF clone in these patients,
the risk factors for LCT are largely unknown.73,74
The classification of LCT of MF is made histologi-
cally when greater than 25% of lymphocytes are
large (>4 times the size of a normal lymphocyte).
These cells may be immunoblastic, pleomorphic,
or Reed-Sternberg cell–like in appearance and
are more often than not CD301. MF with LCT
can be more refractory to treatment, and most
agree that transformed MF portends a worse
prognosis compared with those MF patients
without transformed disease especially if transfor-
mation is found in the lymph nodes in addition to
the skin. For these reasons, more aggressive ther-
apy is typically warranted in these patients. Me-
dian survival times from transformation to death
ranges from 19 to 36 months in most reports;
however, one study found median survival of
8.3 years.75 The reason for this discrepancy is diffi-
cult to decipher; however, it is known that differen-
tiating MF with LCT from concomitant cALCL can
be challenging, or perhaps these patients with MF
had earlier recognition and more aggressive treat-
ment leading to improved overall survival. Most
patients with MF and LCT benefit from a combina-
tion of skin-directed and systemic therapies.
Bexarotene, IFN, and MTX are options from
NCCN guidelines category A drugs for those pa-
tients with more indolent LCT. NCCN guidelines
suggest choosing a category C systemic drug for
MF with LCT that has more aggressive behavior
(liposomal doxorubicin, gemcitabine, romidepsin,
or pralatrexate).Treatment of Mycosis Fungoides with Large
Cell Transformation
Pralatrexate
Pralatrexate is a folate analogue therapy with a
higher affinity for tumor cells than MTX (Box 3).
Pralatrexate gained FDA approval for the indica-
tion of peripheral T-cell lymphoma (PTCL) and
transformed MF in September 2009. A subgroup
analysis of the original pralatrexate in patients
with relapsed or refractory peripheral T-cell lym-
phoma (PROPEL) study reviewed effectiveness
of pralatrexate in 12 patients with MF with LCT.76
About 25% of patients had an objective response
by independent central review; however, 58% of
patients had a response by investigator assess-
ment. In this study, pralatrexate was well tolerated.
A median of 10 pralatrexate injections were given
at a dose of 30 mg/m2 once weekly for 6 weeks
of a 7-week cycle. Median duration of response
was 4.4 months, and median progression-free sur-
vival was 5.3 months by investigator assessment.
Median survival in this study was 13 months. Mu-
cositis occurred in 58% of patients; however, the
only grade 4 adverse events were fatigue (1 pa-
tient) and thrombocytopenia (1 patient). There
were no toxicity-related discontinuations in this
study; however, mucositis was a dose-limiting
toxicity.
In a separate study, dose-limiting mucositis was
an issue in the patient population with CTCL, and
therefore, a lower-dose regimen, 15 mg/m2, given
Hughey828by IV push for 3 weeks of a 4-week cycle seemed
to be better tolerated and had an overall response
rate of 45% (MF with LCT was not specifically dis-
cussed in this study).76 In addition, starting
supplementation with 1 mg B12 intramuscular in-
jection every 8 to 10 weeks (several weeks before
starting pralatrexate) and daily folic acid, 1 mg,
oral supplementation (started at least 10 days
before pralatrexate) also helps to reduce mucositis
issues. Warm salt water rinses 4 times daily and a
bland diet are also helpful in reducing mucositis. In
addition, prescription mouthwashes containing
antacids, antihistamines, antifungals, and anes-
thetic agents may be used.
Preemptive leucovorin use has been reported to
minimize pralatrexate toxicity without sacrificing
efficacy in a study of 3 patients with MF with
LCT.77 Leucovorin, 50mg, IV single dosewas given
24 hours after eachdoseof pralatrexate, 30mg/m2.
There was no mucositis noted in these 3 patients.
Gemcitabine
Gemcitabine, a purine analogue, has been re-
ported to be successful with intermittent low
doses in the treatment of transformed MF.78 In
this study of 3 patients, doses ranged from 750
to 1000 mg/m2 given by typical regimen on days
1, 8, and 15 of a 28-day cycle and also by dosing
from every other week to even more intermittent
dosing when needed based on tumor growth.
Grade 3 thrombocytopenia was noted in 1 patient,
and all 3 patients experienced grade 4 neutropenia
requiring treatment with granulocyte-macrophage
colony-stimulating factor. Gemcitabine can be
continued long term in a patient with well-
controlled disease and can be combined easily
with skin-directed therapy.
Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin contains doxo-
rubicin encapsulated within liposomes allowing
for accumulation in the area of the neoplasm,
and the pegylation reduces clearance. This
formulation of doxorubicin has fewer cardiac
and renal side effects than nonpegylated formula-
tions. A prospective multicenter study evaluated
patients with advanced or refractory CTCL
treated with pegylated liposomal doxorubicin
once monthly at a dose of 40 mg/m2 IV.79 Of
the 25 patients, 10 had transformed CTCL in
this study. In this subset of transformed disease,
overall response rate was 50% (5 of 10) after 8
treatment cycles (1 was a CR). The other 5 had
progressive disease after 2 to 8 cycles of doxoru-
bicin. The median progression-free survival time
in these patients with transformed CTCL was
2 months. About 80% of the side effects weregrade 1 or 2. The most common side effects
were anemia (36%), asthenia (20%), and
nausea/vomiting (20%). Only 2 patients experi-
enced grade 4 side effects, one with hyperthermia
and the other with hemophagocytosis. The use of
doxorubicin is limited by the maximum life-time
dose, given the associated cardiac side effects
with long-term use of this chemotherapy.
Brentuximab vedotin
The mechanism of action and dosing of this CD30
monoclonal antibody tagged with a chemothera-
peutic agent was discussed earlier as were the de-
tails of the phase 2 study using BV for patients with
CTCL.50 Cases of MF with LCT were included in
this study. Overall response rate (ORR) was 73%,
median time to response was 12 weeks (range,
3–39 weeks), and median duration of response
was 32 weeks (range, 3–93 weeks) for patients
withMF.Of 28 patientswithMF, 15 (54%) achieved
a 50% reduction in the modified severity weighted
assessment tool score with 2 CRs. Patients with
MF responded despite differences in CD30 stain-
ing. There was no correlation found between the
extent of CD30 expression and response. For MF
with LCT, BV tends to work well for the LCT nod-
ules and tumors but less so for the MF patches
and plaques. Therefore, BV may be combined
with skin-directed modalities for MF to achieve
better overall response.
Romidepsin
Romidepsin is a histone deacetylase (HDAC) in-
hibitor. There are no specific reports of romidepsin
use for MF with LCT; however, it is listed in the
category C systemic therapies suggested for MF
with LCT in the NCCN guidelines, as this treatment
modality may be effective for tumor lesions and
patients with refractory CTCL.80–82 The typical
dose is 14 mg/m2 IV on days 1, 8, and 15 of a
28-day cycle. The HDAC inhibitors can be used
in combination with total skin electron beam
(TSEB) and phototherapy, making them a useful
option when a systemic therapy and skin-
directed therapy are needed at the same time.83
Bexarotene
Oral bexarotene has been used successfully in the
treatment of MF with LCT and can be used safely
in the long term without immunosuppression and
with few side effects, making this an attractive
treatment option. The maximum daily recommen-
ded dose is 300 mg/m2; however, lower doses
are often effective.84
Alemtuzumab
Alemtuzumab is a humanized anti-CD52 mono-
clonal antibody proposed to be effective in the
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approved by the FDA only for the treatment of
chronic lymphocytic leukemia. A multicenter retro-
spective analysis of alemtuzumab in advanced
CTCL included 11 patients with transformed dis-
ease among the 39 patients in the study.85 Alemtu-
zumab, 30 mg, was given 2 to 3 times per week for
a median duration of 12 weeks, and the dose was
then transitioned to once weekly for the mainte-
nance phase thereafter (21% IV, 79% SQ injec-
tion). All patients received sulfamethoxazole/
trimethoprim and valacyclovir prophylaxis. The
overall response rate was 51% (70% in sezary
syndrome [SS] and 25% in MF); however, in the
11 patients with transformed disease before
alemtuzumab administration, only 1 had clinical
response to skin tumors. There were 5 additional
patients with SS who experienced transformation
of their CTCL in the skin during the alemtuzumab
treatment. Most patients experienced severe lym-
phopenia, and 69% of patients had at least 1
grade 3 side effect, including 62% with infections.
The conclusion of this study proposed alemtuzu-
mab as an effective treatment option in SS but
ineffective in MF and transformed CTCL. In a
previous study of 8 patients treated with
alemtuzumab, 1 of 8 had LCT MF; however, cyto-
megalovirus infection occurred after the sixth
week of treatment, necessitating discontinuation
of therapy.86 Given these findings, alemtuzumab
is not a first-line treatment of MF with LCT.
Allogeneic stem cell transplant
Autologous stem cell transplant has been disap-
pointing in the primary cutaneous CD301 LPDs
secondary to high relapse rates; however, alloge-
neic transplants have been more successful. A
multicenter retrospective analysis of 37 cases of
advanced-stage primary CTCLs treated with allo-
geneic stem cell transplantation included 20
(54%) transformed MF cases.87 Of these latter
cases, there was a 22% transplant-related mortal-
ity, 56% relapse or progression, 26% progression-
free survival, and 60% overall survival at 2 years.
Previously, success with TSEB and nonmyeloa-
blative (reduced intensity) allogeneic hemato-
poietic stem-cell transplantation had been
reported in a series of 19 patients, 8 of whom
had MF with LCT.88 Of these 8 with LCT, 1 died
of progressive disease, 3 were deceased with
CR, and 4 were alive with 3 CR and 1 PR at the
median follow-up period of 1.7 years (range, 0.8–
7.9 years). In both these series, graft-versus-
lymphoma effect was thought to play a role in
the success of this treatment regimen. Allogenic
stem cell transplant remains an option for severe,
refractory MF with LCT.Combination therapies
Although it is not specifically reported in the litera-
ture, skin-directed therapy used for MF combined
with systemic agents likely provides additional
value in these patients with LCT.
The combination of pralatrexate and bexarotene
was compared with pralatrexate monotherapy in
26 patients, with a reported overall response rate
of 50% versus 33%, respectively. Two patients
with MF with LCT were included in this study,
both of whom had a PR. Pralatrexate, 15 mg/m2,
combined with bexarotene, 150 mg/m2, seemed
to be the best dosing regimen with most accept-
able adverse event profile. Mucositis was the
most common adverse effect. Leucovorin was
used in 3 patients, but this did not seem to affect
the mucositis in the opinion of the investigators.89
Bexarotene in combination with MTX was used
to achieve a CR in a patient with refractory MF
with LCT. Doses started with bexarotene
450 mg/d and MTX 50 mg each week; however,
these doses were reduced secondary to side ef-
fects to bexarotene 300 mg/d and MTX 30 mg
each week. CR was obtained in 9 months with
this regimen.90SUMMARY/PEARLS
Accurate diagnosis and classification of patients
cannot be overemphasized when dealing with
CD301 LPDs. It is important to look for different
types of primary lesions, including in sun-
protected areas. Papules, papules with necrotic
eschars, scaly erythematous patches, plaques,
nodules, and tumors may all coexist, and each
may be a clue to the patient’s diagnosis. The distri-
bution of lesions on the body is also important, with
potential patterns including crops of clustered
papules (suggestive of LyP), solitary or few tumor
nodules (suggestive of cALCL or tumor stage
MF), and tumors in association with patches (sug-
gestive of MF with or without LCT). Understanding
that the CD301 LPDs may coexist, multiple bi-
opsies are often helpful in these patients to fully
evaluate the clinical picture. Close communication
with a dermatopathologist experienced with cuta-
neous lymphoma is imperative in these challenging
cases.91 It is hoped that the patient’s diagnosis will
be clear after clinical evaluation and biopsy; how-
ever, many times, a classification cannot be
made right away. Patience and observing the nat-
ural course of the disease eventually leads to an
accurate diagnosis in most patients. For example,
it is unlikely for MF to have any spontaneous
improvement, whereas this is not uncommon with
cALCL. However, there are always those who do
not fit the box and who may have features of 2 of
Hughey830these CD301 entities. In those cases, it is best to
choose a treatment that is acceptable for both
diagnoses.
One should remember the key concept of treat-
ing CTCL: aggressive chemotherapy yields no bet-
ter results than conservative sequential therapy.92
Skin-directed regimens should be used whenever
possible, but one should also recognize that wide-
spread, multifocal disease likely requires systemic
therapy. When treating a treatment-refractory
case, NCCN guidelines may be used to help guide
the use of a combination regimen if monotherapy
is not successful. Finally, a specialized CTCL
multidisciplinary clinic can be invaluable for diag-
nosis and development of a treatment plan for
these patients.REFERENCES
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